國家衛生研究院 NHRI:Item 3990099045/12079
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 912706      線上人數 : 1208
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/12079


    題名: Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with
    作者: Pelzer, U;Blanc, JF;Melisi, D;Cubillo, A;Von Hoff, DD;Wang-Gillam, A;Chen, LT;Siveke, JT;Wan, Y;Solem, CT;Botteman, M;Yang, Y;de Jong, F;Hubner, R
    貢獻者: National Institute of Cancer Research
    摘要: Background: nal-IRI is a nanoliposomal formulation of irinotecan. In the primary analysis of the pivotal NAPOLI-1 Phase-3 trial, nal-IRI+5-FU/LV significantly improved median overall survival (OS, primary endpoint; 6.1 vs 4.2 months, HR = 0.67, P = 0.012) and progression-free survival (PFS; 3.1 vs 1.5 months, HR = 0.56, P = 0.0001) vs 5-FU/LV alone in mPAC pts previously treated with gemcitabine-based therapy. This analysis evaluates between-treatment differences in quality-adjusted survival using a Q-TWiST approach. Methods: Total survival in NAPOLI-1 intent-to-treat cohort over 12 months was partitioned into time with adverse event grade ≥ 3 toxicity (TOX), time in relapse after disease progression (REL), and time without symptoms or adverse event grade ≥ 3 toxicity (TWiST). Mean Q-TWiST was calculated by multiplying time spent in each health state by its respective utility. In the base-case, the utility for TOX (uTOX), REL (uREL) and TWIST (uTWiST) were set to 0.5, 0.5 and 1.0. Nonparametric bootstrapped 95% CIs were derived. The relative Q-TWiST gain of nal-IRI+5-FU/LV vs mean OS for 5-FU/LV was calculated. Threshold analyses varied uTOX and uTWiST between 0.0 and 1.0. Scenario analysis was conducted using per-protocol (PP) population. Results: Nal-IRI+5-FU/LV (n = 117) vs 5-FU/LV (n = 119) pts had significantly more time in TWiST (mean 3.4 vs 2.4 months) and TOX (1.0 vs 0.3 month) but similar time in REL (2.5 vs 2.7 months). In the base-case, nal-IRI+5-FU/LV pts had a 1.3 months (95% CI: 0.4–2.1; 5.1 vs 3.9) greater Q-TWiST (range threshold analyses: 0.9–1.6 months), with a relative Q-TWiST gain of 24% (range threshold analyses: 17%-31%). In the PP population, Q-TWiST was also significantly superior in MM-398+5-FU/LV pts (Q-TWiST gain = 1.8 months; 95% CI: 0.7–3.0). Conclusions: Within NAPOLI-1, combination of nal-IRI+5-FU/LV resulted in statistically significant and clinically important gains in quality-adjusted survival vs 5-FU/LV alone, confirming the clinical outcome benefit of nal-IRI+5-FU/LV in mPAC.
    日期: 2016-05
    關聯: Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e15732.
    Link to: http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.e15732
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000404665407050
    顯示於類別:[陳立宗] 會議論文/會議摘要

    文件中的檔案:

    沒有與此文件相關的檔案.



    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋